TITLE

RESEARCH HIGHLIGHTS

AUTHOR(S)
Carroll, Suzanne; Hodges, Lisa; King, Cynthia R.
PUB. DATE
July 2006
SOURCE
Oncology Nursing Forum;Jul2006, Vol. 33 Issue 4, p693
SOURCE TYPE
Academic Journal
DOC. TYPE
Other
ABSTRACT
Summarizes research related to oncology. "Once Weekly Oral Alendronate Prevents Bone Loss in Men in Androgen Deprivation Therapy," by J. B. Nelson, S. L. Greenspan et al.; "Thalidomide and Hematopoietic Stem-cell Transplantation for Multiple Myeloma," by B. Barlogie, G. Tricot et al.; "The Value of Serial Arteriography in Osteosarcoma: Delivery of Chemotherapy, Determination of Therapy Duration, and Prediction of Necrosis," by J. W. Cullen, B. A. Jamroz et al.; "Racial/Ethnic Preferences, Sex Preferences, and Perceived Discrimination Related to End-of-Life Care," by S. A. Duffy, F. C. Jackson et al.
ACCESSION #
21372258

 

Related Articles

  • High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Sauerbrey, A; Bielack, S; Kempf-Bielack, B; Zoubek, A; Paulussen, M; Zintl, F // Bone Marrow Transplantation;5/1/2001, Vol. 27 Issue 9, p933 

    In this report, we describe our experience with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in 15 children with relapsed osteosarcoma who were treated by members of the Cooperative Osteosarcoma Study Group. Eight patients received HDC after the first relapse, six...

  • High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma. Hong, C R; Kang, H J; Kim, M S; Ju, H Y; Lee, J W; Kim, H; Kim, H-S; Park, S-H; Park, K D; Park, J D; Shin, H Y; Ahn, H S // Bone Marrow Transplantation;Oct2015, Vol. 50 Issue 10, p1375 

    The article focuses on a study related to chemotherapy and autonomous stem cell transplantation (ASCT) as a treatment of osteosarcoma. Topics discussed include patients undergoing ASCT with melphalan in combination with other drugs; surgical resection of the primary tumor and adjuvant...

  • Breakthrough in Stem Cell Therapy.  // India -- West;7/16/2010, Vol. 25 Issue 34, pA41 

    The article reports on the success of an autologous stem cell-based therapy procedure in a nine-month-old dog conducted by researchers at Tamil Nadu Veterinary and Animal Sciences in India.

  • Carboplatin/etoposide: Intrapulmonary haemorrhage: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p96 

    A 71-year-old woman developed pruritus and acneiform skin rash during treatment with erlotinib for lung adenocarcinoma. Additionally, the acneiform skin rash and pruritus worsened following concomitant administration of erlotinib and aprepitant for lung adenocarcinoma.

  • Danazol as first-line therapy for aplastic anemia. Jaime-Pérez, José Carlos; Colunga-Pedraza, Perla R.; Gómez-Ramírez, Cynthia D.; Gutiérrez-Aguirre, César H; Cantú-Rodríguez, Olga G.; Tarín-Arzaga, Luz C.; Gómez-Almaguer, David // Annals of Hematology;May2011, Vol. 90 Issue 5, p523 

    Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) is the standard treatment for aplastic anemia (AA) patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT). In the absence of ATG + CsA, androgens continue to be a treatment...

  • Assessing agreement between CD34 enumeration by flow cytometry and volumetric analysis. Gisselo, C.G.; Roer, O.; Hoffmann, M.H.; Hansen, M.B.; Taaning, E.; Johnsen, H.E. // Bone Marrow Transplantation;4/15/2002, Vol. 29 Issue 8, p699 

    Presents information on a study which compared the methods for CD34 enumeration, namely flow cytometry and volumetric analysis. Significance of comparing both methods for stem cell mobilization; Materials and methodology of the study; Results and discussion.

  • Hematopoietic stem cell transplantation for hematological malignancies in Europe. Gratwohl, A; Baldomero, H; Passweg, J; Frassoni, F; Niederwieser, D; Schmitz, N; Urbano-Ispizua, A // Leukemia (08876924);May2003, Vol. 17 Issue 5, p941 

    Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transplant numbers have increased five-fold during the last decade. Only a few controlled prospective studies are available, and different opinions prevail. Data from 118...

  • Fanconi Anemia: 29 Years Experience in a Single Center. AZIK, Fatih M.; ILERI, Talia; INCE, Elif U.; ERTEM, Mehmet; UYSAL, Zumrut; GOZDASOGLU, Sevgi // International Journal of Hematology & Oncology / UHOD: Uluslarar;Dec2010, Vol. 20 Issue 4, p201 

    Hematopoietic stem cell transplantation, which is the only curative therapy for marrow failure experienced by Fanconi anemia, was not available for all patients due to lacking in adequate transplantation centers in Turkey in the past years. For this reason, although androgens side effects are...

  • VP23 The New Cancer Drugs Fund: The Future Model Of Oncology Reimbursement. Walsh, Sean; Macaulay, Richard; Turkstra, Erika; Tsang, Ricky // International Journal of Technology Assessment in Health Care;2018 Supplement, Vol. 34, p165 

    Introduction: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable patients to access oncology therapies that are not routinely publicly funded. In April 2016, the CDF became a temporary reimbursement fund under the remit of the National Institute for Health and Care Excellence...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics